Stay updated on Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Sign up to get notified when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.

Latest updates to the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page
- CheckyesterdayChange DetectedFooter revision tag updated from v3.4.0 to v3.4.1. No changes to study information or navigation.SummaryDifference0.0%

- Check8 days agoChange DetectedAdded Show glossary toggle; updated metadata labels to include 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with Revision set to v3.4.0, and removed the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and Revision: v3.3.4.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page now includes expanded Locations with new site entries across Alabama, Connecticut, Florida, Minnesota, Missouri, Ohio, Virginia, New South Wales, South Australia, and Victoria. The HHS Vulnerability Disclosure link was removed and the revision is updated to v3.3.3.SummaryDifference0.7%

- Check72 days agoChange DetectedPublications section wording updated to say publications are automatically filled from PubMed, and revision labels changed from v3.2.0 to v3.3.2. These are minor text and version updates to the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedRemoval of the broad government funding lapse notice from the page; this change does not affect the study details or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.